Background {#Sec1}
==========

Rising carbon emissions due to increased industrialization and its effect on the climate are raising awareness to organize our economy in more sustainable ways. However, to transition from our current fossil resource-based economy to a bio-based economy is not easily achieved given the huge dependency on fossil fuels for energy and commodity needs. Biotechnologically produced organic acids have great potential as sustainable alternative for petrochemicals and its use as commodities \[[@CR1]\]. The main bottleneck for industrial application of biochemicals, however, is the high price compared with petrochemicals. Many yeasts and bacteria have been exploited in the production of industrially relevant biochemicals, e.g. succinic acid \[[@CR2]\]. However, filamentous fungi are due to their natural lifestyle as saprophytic organisms well equipped to break down complex carbohydrate structures e.g. lignocellulose and produce industrially relevant biochemicals. Apart from this fact filamentous fungi are also known as efficient organic acid producers, in particular members of the genus *Aspergillus* \[[@CR3]\].

Itaconic acid (IA), a C5-dicarboxylic acid, has previously been identified as one of the top twelve biochemicals that can be produced by biotechnological means \[[@CR4]\]. The potential applications of IA in green chemistry are numerous and an exciting overview of novel applications is provided by Robert and Friebel \[[@CR5]\]. Industrial production of IA is performed using the natural producer *A*. *terreus*. Currently IA and its chemical derivatives are seen as niche chemical with low industrial relevance. The main applications of IA and its chemical derivatives are as superabsorbent polymers, synthetic latex, detergent builders, polymers and polyester resins \[[@CR6], [@CR7]\]. Lowering production costs and selling price of IA could result in the promotion of IA into a platform chemical that would lead to an tenfold increase in its market size and open market applications such as thermoplastics \[[@CR8], [@CR9]\]. In order to achieve this feat the selling price of IA should be competitive with fossil-based end use chemicals such as maleic anhydride. The high production cost and selling price of IA can be attributed to the sensitivity of *A*. *terreus* to impurities in industrial cultivation medium and tight control of fermentation processes \[[@CR10]--[@CR12]\].

Heterologous IA production in the related species *Aspergillus niger* has been proposed earlier based on the superior organic acid production capabilities of *A*. *niger* as exemplified by industrial citric acid (CA) production that mainly employs *A*. *niger* \[[@CR13]--[@CR15]\]. Additionally *A*. *niger* is a more robust production organism able to withstand impurities in industrial cultivation medium; a feat that is evident by the low selling prices of biotechnologically produced CA \[[@CR16], [@CR17]\]. In our previous report we have communicated the rewiring of *A*. *niger* secondary metabolism citrate synthase (CitB) leading to an increased IA yield, titer and productivity \[[@CR18]\]. Metabolic engineering of ATP-citrate lyase in our rewired pathway has resulted in further improvement of IA production (Hossain AH et al. manuscript in preparation). However, we also observed in cultivations with these engineered strains that IA titer reaches a plateau after which titers start to decline rapidly (Hossain AH et al. manuscript in preparation). This decline in IA is supposedly brought about by putative IA bioconversion. In order to determine the genes responsible for IA bioconversion a transcriptome analysis was performed. In combination with a previous transcriptome analysis of primary metabolism genes related to glycolysis, TCA cycle and organic acid transport (de Vries et al. \[[@CR3]\]), this analysis led to the identification of previously unknown genes of which the expression is highly upregulated in IA producing conditions.

Materials and methods {#Sec2}
=====================

Strains and media components {#Sec3}
----------------------------

*Aspergillus niger* strain CitB\#99 (CBS141659) \[[@CR18]\] was used in this study in which deletion of *ictA*, *ichA* and *tmtA* was performed. The strains used for transcriptome analysis are listed in Table [1](#Tab1){ref-type="table"}. All strains were stored in 30% glycerol at − 80 °C and maintained on agar containing minimal medium (MM) plates (16 g/L agar, 6 g/L NaNO~3~, 0.52 g/L KCl, 1.52 g/L KH~2~PO~4~, 10 g/L glucose, 0.0022 g/L ZnSO~4~.7H~2~O, 0.0011 g/L H~3~BO~3~, 0.0005 g/L MnCl~2~.4H~2~O, 0.0005 g/L FeSO~4~.7H~2~O, 0.00017 g/L CoCl~2~.6H~2~O, 0.00016 g/L CuSO~4~.5H~2~O, 0.00015 g/L NaMoO~4~.2H~2~O, 0.005 g/L Na~2~EDTA and 0.5 g/L Mg~2~SO~4~). Spore suspensions were prepared using physiological salt solution (0.9% NaCl) and stored at 4 °C for up to 1 year. Fresh spore suspensions were prepared for inoculation during each shake flask and batch fermentation experiment.Table 1List of strains used for transcriptome analysisStrainAbbreviationStrain descriptionAB1.13 *pyrG*+AB1.13Uridine prototroph of AB1.13 *pyrG*---\[[@CR19]\]AB1.13 CAD 4.1AB1.13 CADSelected pyrG + transformant of *cadA* expressing transformant (CAD10.1) of AB1.13 \[[@CR20]\]AB1.13 CAD + MTT + MFS_3AB1.13 CAD + MTT + MFSSelected *mfsA* expressing transformant of MTT 1.4 \[[@CR19]\]AB1.13 CAD + MFS + MTT \#49B;AB1.13 \#49BSelected *mttA* expressing transformants of AB1.13 CAD + MFS 3.9 \[[@CR18]\]AB1.13 CAD + MFS + MTT + CitB \#99; \#113CitB\#99; CitB\#113Selected *citB* overexpressing transformants of AB1.13 CAD + MFS + MTT \#49B \[[@CR18]\]

Split marker deletion construct and transformation {#Sec4}
--------------------------------------------------

Auxotrophic *pyrE*-strains were generated by cultivating CitB\#99 on 5-fluoroorotic acid selective plates \[[@CR21]\]. Plates were incubated in a 33 °C stove for 3--5 days until colony formation was visible. Organic acid production of CitB\#99 *pyrE*-colonies was tested by cultivation in microtiter plates (see section screening). Knock-out of *ictA*, *ichA* and *tmtA* was performed using the split-marker method \[[@CR22]\]. An schematic overview of the split-marker approach is shown in Additional file [1](#MOESM1){ref-type="media"}. Split-marker flanks for an *ictA* and *ichA* knock-out were generated with fusion PCR and split-marker flanks for a *tmtA* knock-out were in vitro synthesized by GeneArt Gene Synthesis (Thermo Scientific) and individually introduced into pJET1.2/blunt via blunt-end ligation using the CloneJET PCR Cloning Kit (Thermo Scientific). The primers used to create the split-marker fragments for *ictA* and *ichA* are listed in Additional file [2](#MOESM2){ref-type="media"}. The *pyrE* gene of *Aspergillus oryzae* RIB40 (AO090026000521) was employed to complement the *pyrE* deficient phenotype. The split-marker fragments were co-transformed in an ratio of 1:1 (5 µg flank 5′: 5 µg flank 3′). All transformations were carried out according to the protocol as reported by Punt et al. \[[@CR23]\]. Transformed protoplasts were plated on MM agar plates containing sorbitol and grown at 33 °C for 3--5 days until colonies were visible. Successful targeted integration of bi-partite fragments were determined with diagnostic colony PCR \[[@CR24]\] using various primer combinations. Colonies that showed the expected PCR fragments were selected for further screening in microtiter plate and shake flask experiments.

Microtiter plate transformant screening {#Sec5}
---------------------------------------

Plates carrying transformed cells were allowed to grow and sporulate for 1--2 weeks after which individual colonies were transferred to a selective MM plate. Individual colonies from this plate were each streaked on a separate selective MM plate to isolate single colonies that in turn were used to inoculate 1 mL liquid cultures in a 96-wells deepwell plate (Axygen; Corning, NY) containing M12 ++ medium (1.43 g/L NH~4~NO~3~, 0.11 g/L KH~2~PO~4~, 0.5 g/L MgSO~4~ × 7 H~2~O, 0.005 g/L CuSO~4~ × 5 H~2~O, 0.0006 g/L FeIIICl~3~ × 6 H~2~O, 0.0006 g/L ZnSO~4~ × 7 H~2~O, 0.074 g/L NaCl, 0.13 g/L CaCl~2~ × 2 H~2~O and 100 g/L glucose) \[[@CR20]\]. This 96-wells plate was incubated for 72 h at 33 °C and 850 RPM. Supernatant was filtered over a 0.22 µM filter (Corning; Corning, NY) and analyzed on an HPLC for IA production (see below).

Flask cultivations {#Sec6}
------------------

MM agar plates were streaked with conidia from glycerol stocks or from isolated single colonies that were determined by colony PCR. These plates were incubated at 33 °C for several days till plates were fully grown. Fresh conidia suspensions were prepared by harvesting conidia from these plates with sterile 0.9% NaCl solution. The harvested conidia were counted on the LUNA II cell counter (Logos Biosystems). Non-baffled shake flasks (500 mL) were filled with 100 mL M12 ++ medium and inoculated with 1.0 × 10^6^/mL conidia and incubated at 35 °C and 0 RPM. Flasks were weighed when empty, after inoculation and each day before sampling. Evaporation is calculated from the measured weight of the flasks and used to correct measured concentrations of organic acids and glucose by HPLC (see below). Error bars in graphs of flask cultivations indicate the standard error of the mean. All flask cultivations were performed in duplicate.

Controlled-batch cultivations {#Sec7}
-----------------------------

Controlled-batch cultivations were performed on 5L scale benchtop New Brunswick Scientific fermenters (BioFlo 3000) at 33 °C. Starting pH was 3.5 after inoculation and medium was allowed to naturally acidify till pH 2.3 and then kept at pH 2.3 by addition of 4 M KOH. Dissolved oxygen (DO) tension was 25% at the moment of inoculation and when DO dropped till 20% it was kept at 20%. The system was calibrated with 100% sterile air as 100% DO and 100% N~2~ as 0% DO. The fermenter was inoculated by 72 h old 100 mL non-baffled shake flask cultures containing 1.0 × 10^8^ spores. Medium composition for fermentation and pre-culture (M12 ++) is described above.

HPLC {#Sec8}
----

Metabolite analysis was performed using a WATERS e2695 Separations Module equipped with an Aminex HPX-87H column (Bio-Rad) and 5 mM H~2~SO~4~ as eluent. Detection of peaks occurred simultaneously by a refractive index detector (WATERS 2414) and a dual-wavelength detector (WATERS UV/Vis 2489). Data processing was done with Empower Pro software (Empower 2 Software, copyright 2005--2008, Waters Corporation, Milford, MA, USA).

RNA isolation and transcriptome analyses {#Sec9}
----------------------------------------

Biomass samples for RNA isolation were taken at several time points during fermentation and washed with distilled water and frozen in liquid N~2~. The mycelium was disrupted by bead-beating with 0.1 mm acid-washed Zirconium-Silica beads and RNA extraction proceeded using the ChargeSwitch RNA extraction protocol from Invitrogen (Carlsbad, CA, USA). Quality control was checked on 1 × 3-(*N*-morpholino)propanesulfonic acid/6% Formaldehyde agarose gels and stained with ethidium bromide.

BaseClear in Leiden, NL performed digital gene expression profiling experiments based on RNA-Seq with an Illumina HiSeq 2000 System. Approximately 8--32 M unfiltered paired-end (PE) reads (99 bp/read on \~ 320 bp cDNA inserts) were obtained. Reads were trimmed of the first 2 bases of the 5′ end because these bases showed an aberrantly low GC content. The reads were then further filtered, such that all quality Phred scores after filtering are at least 22, with a read-length of at least 40 bases. Around 70--80% of the bases passed these criteria (including a 2% loss because of clipping). After filtering the \# PE-reads/samples were between 7.6 and 19.8 M for all the samples respectively.

Reads were aligned to the 20 contigs in a FastA file of the *Aspergillus niger* CBS 513.88 reference genome (from <http://www.ebi.ac.uk/ena>). Source EMBL annotations were converted to GFF format. The embl data appeared to be derived from multiple sources with different feature tags. These were converted to one uniform GFF format that could be accepted by our third-party software (consistent gene_ids across all contigs). Missing gene definitions (e.g. inserted genes for IA production) were inserted. The reads were aligned to the reference genome using software based on a Burrows--Wheeler Transform (BWT) algorithm. A mismatch rate of 4% was allowed for the alignment. The maximum insertion length was 3. The maximum deletion length was 3. All samples had more than 85% of the reads aligned, resulting in SAM alignment files. Gene expression was measured as the number of aligned reads to reference genes and was normalized to RPKM values (Reads Per Kb per Million reads; Mortazavi et al. \[[@CR25]\]). Hierarchical clustering was performed with TIGR MEV 4.0. A stringent cut-off at 2logR value of 4.0 for upregulated genes and − 4.0 for downregulated genes was held for data analysis. A more relaxed cutoff of \> 2.0 or smaller − 2.0 was used to explore the data for identifying novel differentially expressed gene clusters.

Results {#Sec10}
=======

Transcriptome analysis of high IA producing *A*. niger strains {#Sec11}
--------------------------------------------------------------

Previously we have reported the IA production of *A*. *niger* strain CitB\#99 that reaches a final titer of 26.2 g/L with max productivity of 0.35 g/L/h and yield of 0.37 g/g \[[@CR18]\]. IA production was further improved by metabolic engineering of ATP-citrate lyase (Hossain et al. \[[@CR18]\]). Remarkably, we have also observed IA bioconversion in *A*. *niger* during IA producing cultivations. This observation manifested in strongly reduced IA titers after achieving a peak IA titer. In addition, IA bioconversion was also observed in cultures were exogenous IA was added to shake flask cultures, showing a reduction of IA levels (Additional file [3](#MOESM3){ref-type="media"}). In order to identify the genes involved in IA bioconversion we have analyzed a transcriptome dataset of biomass isolated from batch fermentations with low, medium and high IA producing *A*. *niger* strains. In Table [2](#Tab2){ref-type="table"} transcriptome results of differentially regulated genes between the high IA producing strain CitB\#99 and AB1.13 WT, that does not produce IA, is given. As expected, the four genes that constitute the engineered part of the heterologous IA biosynthesis pathway i.e. *cadA*, *mfsA*, *mttA* and *citB* are all highly expressed in CitB\#99 (Table [2](#Tab2){ref-type="table"}A).Table 2Differential expressed genes in high IA producing strainsA2logR valuesRPKM valuesLocus tagOld locus tagAnnotationTargetPAB1.13AB1.13 CADAB1.13 \#49BCitB\#99AB1.13AB1.13 CADAB1.13 \#49BCitB\#99ANI_1\_1474074An08g10920Citrate synthase (CitB)Cytosol0.020.04− 0.0511.403.053.102.8710,838.65*cadA* (*A*. *terreus*)Cis-aconitate decarboxylaseCytosol0.0510.629.4710.723.546887.963116.067417.64ANI_1\_1906104An12g05750MFS phosphate transporterPM0.131.0210.2810.551.092.872375.802852.93*hph* (S. hindustanus)Hygromycin B 4-*O*-kinaseCytosol0.230.178.8410.040.940.86759.611743.36*mttA* (*A*. *terreus*)Putative mitochondrial tricarboxylite transporterMito− 0.180.188.469.860.190.54477.021257.78*mfsA* (*A*. *terreus*)Putative major facilitator superfamily transporter APM0.071.447.499.190.302.36222.56721.88*amdS* (A. nidulans)Acetamidase ACytosol0.008.577.577.900.37517.76259.47325.00ANI_1\_2022014An01g14940Phospholipase C PLC-CSecreted0.060.084.997.188.408.53286.391310.11ANI_1\_1486074An08g110303-Phytase BSecreted− 0.030.215.946.9927.3632.281771.343663.34ANI_1\_2368024An02g02840SialidaseSecreted− 0.050.067.226.810.210.30184.78139.52ANI_1\_236084An09g02180LipaseSecreted/Mito− 0.34− 0.303.966.782.432.5567.01479.51ANI_1\_1848144An16g06190Metabolite transport protein GIT1PM0.040.736.806.466.8111.62846.83669.87ANI_1\_166144An16g01340Glyoxalase domain-containing protein 5Mito/Cytosol0.244.705.706.2016.28379.47761.691080.98ANI_1\_248124An14g01550Acid phosphataseSecreted− 0.16− 0.274.915.894.203.82174.16345.29ANI_1\_1500104An12g02320Short-chain dehydrogenase/reductaseCytosol0.013.074.705.652.3326.6384.56164.88ANI_1\_1330084An09g03700Hypothetical proteinSecreted− 0.140.104.055.640.460.7225.7279.39ANI_1\_460094An11g03340Alpha-amylase A type-1/2Secreted− 0.120.331.565.5212.8017.8143.27683.63ANI_1\_542164An18g04140Acid phosphataseSecreted0.040.074.045.501.421.4537.62104.94ANI_1\_1576144An16g02440Phytase-likeSecreted− 0.030.044.275.483.984.2397.10226.06ANI_1\_260144An16g01850BYS1 domain proteinSecreted− 0.64− 0.162.355.309.2213.1979.91623.78ANI_1\_1250124An14g02660NPP1 domain proteinSecreted0.120.244.085.293.113.4863.27147.19ANI_1\_2836024An02g08830Histone transcription regulator 3Nucleus0.000.09− 0.035.159.4810.119.28371.63ANI_1\_652114An13g01750Acid phosphataseSecreted0.060.104.675.1370.7372.831754.062422.06ANI_1\_1440124An14g04660Aromatic ring-opening dioxygenase, catalytic LigB subunitCytosol/Mito/Per0.130.320.325.132.593.103.09113.67ANI_1\_1432064An07g00760Putative itaconyl-CoA transferase (ictA)Mito0.323.273.925.0613.07108.35170.34375.89ANI_1\_1812184An04g04240Phosphate transporterPM0.271.054.834.992.945.7491.74102.55ANI_1\_126034An03g01120Aromatic-amino-acid aminotransferaseNucleus− 0.343.624.244.9829.79478.24735.441226.92ANI_1\_246114An13g01760Oligopeptide transporterPM0.330.462.434.971.301.518.8856.23ANI_1\_1908104An12g05810Multicopper oxidaseSecreted0.040.204.334.760.180.3121.9830.01ANI_1\_2118064An07g09220Putative itaconyl-CoA hydratase (ichA)Mito− 0.112.784.044.717.3260.28146.61232.65ANI_1\_1324074An08g09850Acid phosphataseSecreted− 0.18− 0.363.704.58128.06112.961896.573490.63ANI_1\_1520134An15g04760Glycosyl hydrolase family 71 proteinSecreted− 0.29− 0.822.214.571.580.7913.6874.04ANI_1\_2122184An04g08320MFS monocarboxylate transporterPM0.170.491.254.467.119.1616.14158.52ANI_1\_3198024An02g13080Phenylacetate-coenzyme A ligaseCytosol− 0.28− 0.510.354.280.270.080.9628.87ANI_1\_1430064An07g00750Fungal transcription factorNucleus/Mito0.023.043.734.280.5211.3719.0128.19ANI_1\_820034An03g06550GlucoamylaseSecreted0.13− 0.021.764.18243.81218.86756.844054.75ANI_1\_1020134An15g07520Phosphoglycerate mutase family proteinCytosol− 0.20− 0.604.754.1812.679.31420.93282.80ANI_1\_1810184An04g04230Phosphate transporter (reannotated)Nucleus/Cytosol− 0.180.334.604.174.677.06154.52114.01ANI_1\_294044An05g02340Extracellular dihydrogeodin oxidase/laccaseSecreted− 0.08− 0.074.484.110.440.4432.9625.14ANI_1\_864144An16g06510Trans-aconitate 2-methyltransferase (tmtA)Cytosol0.080.732.404.0812.7120.5167.34218.46ANI_1\_342114An13g02590Sugar transporterPM− 0.010.282.164.063.214.1618.0169.60ANI_1\_1098184An04g06920Alpha-glucosidaseSecreted0.00− 0.330.574.04174.34138.54258.872884.10ANI_1\_1820094An11g03450Small secreted proteinSecreted0.331.682.254.0258.07149.69222.30763.49ANI_1\_330024An02g02480MFS phosphate transporterPM− 0.201.653.184.023.1213.8241.8675.60ANI_1\_762014An01g05900Cytochrome P450Secreted− 0.13− 0.103.864.000.630.6624.9727.63ANI_1\_1778074An08g02590GPI anchored proteinSecreted− 0.060.213.264.0010.6213.07115.12192.81B2logR valuesRPKM valuesLocus tagOld locus tagAnnotationTargetPAB1.13AB1.13 CADAB1.13 \#49BCitB99AB1.13AB1.13 CADAB1.13 \#49BCitB99ANI_1\_542134An15g03800HydrophobinSecreted0.06− 0.55− 2.13− 8.78981.57641.93213.111.14ANI_1\_1416134An15g04010Hypothetical proteinNucleus0.27− 0.20− 5.87− 7.79288.73208.033.110.09ANI_1\_92174An10g00820Oxaloacetate acetylhydrolaseCytosol− 0.13− 0.81− 2.61− 7.511803.481122.69323.449.81ANI_1\_220174An10g00800Purine nucleoside permeaseSecreted− 0.13− 0.33− 2.72− 6.47375.32326.2561.403.64ANI_1\_1046034An03g01450Major Facilitator SuperfamilyPM− 0.20− 0.83− 2.49− 6.2973.8347.1814.310.10ANI_1\_1062034An03g01590Arginine permeasePM0.130.41− 2.09− 6.08243.24295.3951.562.30ANI_1\_964034An03g00580Cytochrome P450 monooxygenaseMito− 0.29− 1.86− 3.52− 6.00228.7476.0523.453.39ANI_1\_966034An03g00590Trichodiene synthase Tri5Cytosol− 0.31− 2.27− 4.02− 5.8794.1123.356.271.01ANI_1\_170034An03g014601-Aminocyclopropane-1-carboxylate oxidaseCytosol− 0.10− 0.86− 2.52− 5.43114.8167.3520.611.88ANI_1\_1914064An07g06460C-7 hydroxycephem methyltransferaseCytosol− 0.26− 0.32− 4.38− 5.2836.4735.031.160.16ANI_1\_182034An03g01540FAD dependent oxidoreductaseSecreted/Cytosol0.05− 0.42− 1.58− 5.2678.9456.6924.801.02ANI_1\_1770144An16g05290Purine-cytosine permeasePM− 0.050.00− 1.13− 5.22838.03867.97395.4522.38ANI_1\_990084An09g00660OPT oligopeptide transporter proteinPM0.010.10− 0.27− 5.09279.04298.75230.297.20ANI_1\_2008094An11g05190Type 1 glutamine amidotransferaseCytosol− 0.020.24− 1.25− 5.0670.0684.1229.321.16ANI_1\_1366064An07g00170Hypothetical proteinSecreted0.370.34− 1.87− 5.0456.1454.9611.100.35ANI_1\_1572014An01g11640Ammonium transporterPM0.220.03− 1.36− 5.02222.82195.3074.164.91ANI_1\_1862104An12g05440Urea active transporter 1PM− 0.15− 0.26− 2.63− 5.0168.0463.0911.381.38ANI_1\_2238104An12g09660Phosphoribosyl transferaseCytosol0.640.85− 1.49− 4.94126.25145.4327.941.66ANI_1\_1456124An14g04760Male sterility domain containing proteinCytosol0.26− 0.49− 2.51− 4.91258.07152.7736.936.18ANI_1\_708024An02g05060Hypothetical proteinSecreted− 0.03− 1.15− 1.98− 4.81810.00371.87208.6728.41ANI_1\_2764024An02g08200Short-chain dehydrogenase/reductaseCytosol1.052.54− 0.64− 4.80308.27867.2894.684.34ANI_1\_2236104An12g09640Uracil-regulated protein 1Cytosol0.440.67− 0.72− 4.80107.20125.8247.451.86ANI_1\_46014An01g00370Aspartic endopeptidase (AP1)Nucleus0.10− 0.18− 1.58− 4.791351.681115.18422.5444.77ANI_1\_1054034An03g0152012-oxophytodienoate reductaseMito− 0.03− 1.01− 1.20− 4.7142.1620.8218.170.68ANI_1\_1850094An11g03640OPT oligopeptide transporter familyPM− 0.11− 0.52− 0.49− 4.71104.2378.3479.933.35ANI_1\_1990074An08g05320Short-chain dehydrogenase/reductaseCytosol− 1.43− 1.61− 3.15− 4.7016.5014.514.330.82ANI_1\_474154An17g01540GABA permeasePM0.070.26− 2.34− 4.6785.8298.2815.402.26ANI_1\_1748104An12g04260NAD dependent epimerase/dehydrataseMito1.232.79− 2.00− 4.6669.28206.656.500.19ANI_1\_726064An07g05830FormamidaseCytosol− 0.030.02− 0.57− 4.58267.27276.94184.4010.45ANI_1\_3344014An01g14400Cercosporin toxin resistance protein CRG1Cytosol0.040.02− 2.87− 4.5663.0562.217.561.65ANI_1\_176044An05g01410Acyl-CoA oxidaseMito− 0.30− 0.96− 2.25− 4.55178.03111.6045.078.38ANI_1\_568054An06g02150DUF3328 proteinSecreted0.110.34− 4.28− 4.5548.4957.101.360.96ANI_1\_1554124An14g05980MFS transporterPM0.010.48− 3.43− 4.5429.1240.791.780.29ANI_1\_1048034An03g01470[d]{.smallcaps}-galactonate transporterPM− 0.07− 1.24− 2.35− 4.5237.5316.206.960.76ANI_1\_806074An08g05670Nitrate transporterPM0.131.08− 1.66− 4.4444.1586.1712.000.90ANI_1\_3376014Fe(II)/2-oxoglutarate (2OG) oxygenaseCytosol− 0.17− 0.07− 1.01− 4.3897.28104.7854.144.31ANI_1\_1340084An09g03750MAC/Perforin domainCytosol0.100.11− 2.61− 4.3722.5822.732.580.06ANI_1\_1514034An03g060204-Carboxymuconolactone decarboxylaseCytosol0.19− 0.43− 1.29− 4.315568.623603.741987.79245.12ANI_1\_2954014An01g09970Surface layer proteinCytosol0.37− 0.03− 1.62− 4.2966.3750.0516.011.67ANI_1\_2450014An01g03790Urea active transporter 1PM− 0.05− 0.17− 0.10− 4.29116.82107.59113.285.27ANI_1\_616114An13g01470Laminin gamma 3Secreted− 0.15− 1.01− 2.79− 4.27110.9360.5916.955.42ANI_1\_1456104An12g01910PhytaseSecreted− 0.04− 0.95− 4.39− 4.2630.6915.780.550.70ANI_1\_142174An10g00180Cupin_likeCytosol/Mito0.34− 0.10− 1.24− 4.24424.35310.92140.9016.72ANI_1\_1362014An01g09980Asp-hemolysinSecreted0.32− 0.14− 1.07− 4.21347.94252.51132.2114.06ANI_1\_878114An13g03990Nucleobase-cation-symport-1 (NCS1) transporterPM− 0.080.15− 2.27− 4.2130.6636.145.910.81ANI_1\_2456094*S*-adenosylmethionine-dependent methyltransferase0.08− 0.27− 3.01− 4.2069.2754.397.292.63ANI_1\_2086074An08g07010DUF3445 proteinMito0.00− 0.25− 2.44− 4.1737.0731.016.011.11ANI_1\_212174Nitrilase− 0.38− 0.59− 2.64− 4.1218.9216.233.150.49ANI_1\_1828184An04g04370Phenylalanine ammonia-lyasePM0.17− 0.10− 2.11− 4.11277.24229.8456.4413.37ANI_1\_76154An17g00640Zinc-binding alcohol dehydrogenase domain-containing protein cipBCytosol1.042.86− 2.13− 4.11119.10425.4412.362.40ANI_1\_1094134An15g00280Polysaccharide deacetylaseCytosol0.00− 0.07− 0.98− 4.08204.72194.38102.7211.10ANI_1\_1144084An09g01920FAD binding domain proteinSecreted0.752.11− 1.49− 4.0439.96103.977.670.48ANI_1\_294064An07g02310Glutathione *S*-transferase Ure2-like proteinCytosol0.01− 0.86− 2.83− 4.02187.81102.9425.4210.62(A) Genes upregulated in high IA producing conditions. Cutoff of 2logR values of 4.00 or higher was held. (B) Genes downregulated in high IA producing conditions. Cutoff of 2logR values of − 4.00 was held

Interestingly, among the highly upregulated genes are a large number of genes that encode gene products with domains that have functions in phosphate liberation and translocation. This result is in line with the fact that in the IA production medium phosphate is limiting \[[@CR26]\]. Remarkably, also the expression of major secreted enzymes such as amylase and glucoamylase, but also a number of other secreted proteins is upregulated in high IA producing conditions. The mechanism behind this result is not entirely clear, but may also be related to the fact that in high IA secretion conditions stress responses are induced which may lead to improved protein secretion (Table [2](#Tab2){ref-type="table"}A) \[[@CR27], [@CR28]\]. Upon closer inspection of the results and in particular when expanding the results using a more relaxed cut-off, many of the upregulated and down regulated genes are clustered together in the genome in putative metabolic pathway clusters. This becomes even more apparent when we look at all genes for which the cut-off for differential expression is 2log = 2. Several phosphate and iron related gene clusters were identified showing co-induction in high IA producing strains (Additional file [4](#MOESM4){ref-type="media"}).

Heterologous IA production in *A*. *niger* also results in the downregulation of many genes compared with the AB1.13 strain (Table [2](#Tab2){ref-type="table"}B). In relation to organic acid production it is interesting to note that the expression of the *oahA* gene coding for oxaloacetate acetylhydrolase, the enzyme that hydrolyses oxaloacetate into oxalate and acetate, is downregulated in CitB\#99. This observation is in line with our previous report were oxalic acid could not be detected in batch fermentations of CitB\#99 \[[@CR18]\]. Upon closer inspection also genes encoding malate synthase and isopropylmalate synthase are downregulated, assuming further rewiring of the organic acid pathway in our IA production hosts (Additional file [5](#MOESM4){ref-type="media"}). Remarkably among the downregulated genes are many that are involved with N transport and utilization. This could be caused by the use of NH~4~SO~4~, as sole N-source in IA production media, which could mediate nitrogen metabolite repression under high IA production conditions. In closer inspection of the selection of genes showing at least fourfold repression in IA overproducing strains besides the many N-source utilisation related functions (permeases etc.) also several secondary metabolite gene clusters were identified (Additional file [5](#MOESM5){ref-type="media"}).

Interestingly, in high IA producing conditions CitB\#99 upregulates the expression of An07g00760 and An07g09220, when compared to AB1.13. This upregulation can already be observed in AB1.13 CAD strain that produces low titers of IA (Table [3](#Tab3){ref-type="table"}) \[[@CR20]\]. Genes An07g00760 and An07g09220 share sequence similarity with ATEG_06299 and ATEG_03709 that are identified in *A*. *terreus* as genes responsible for the biological degradation of IA \[[@CR29]\] (Additional file [6](#MOESM6){ref-type="media"}). Sasikaran et al. \[[@CR30]\] have also elucidated a similar pathway in pathogenic bacteria, suggesting a role in pathogenicity. As Chen et al. show the product of genes ATEG_06299 and ATEG_03709 are itaconyl-CoA transferase (IctA) and itaconyl-CoA hydratase (IchA) that together with citramalyl-CoA lyase (CclA) (ATEG_03186) degrade IA into the cellular building block chemicals pyruvate and acetyl-CoA. In *A*. *terreus* all three genes *ictA*, *ichA* and *cclA* are induced whereas in *A*. *niger* only *ictA* and *ichA* are induced. In contrast to what may have been expected for a catabolic pathway of a secondary metabolite as IA is, these IA bioconversion genes are not clustered in the genome of *A*. *niger*. More dedicated sequence analysis of the encoded proteins reveal that all three carry predicted mitochondrial targeting sequences, suggesting that IA conversion occurs in this compartment.Table 3Transcriptome data of genes involved in IA biosynthesis and bioconversionLocus tagEnzymeOld locus tagTargetPAB 1.13 WTAB 1.13 CADAB1.13 \#49BCitB\#99RPKMRPKMRPKMRPKM*IA biosynthesis cluster*Major facilitator superfamily transporter (*mfsA*)PM0.302.36222.56721.88Cis-aconitate decarboxylase (*cadA*)Cytosol3.546887.963116.067417.64Mitochondrial tricarboxylite transporter (*mttA*)Mito0.190.54477.021257.78*Citrate synthase*ANI_1\_876084Citrate synthase (*citA*)An09g06680Mito284.82269.02255.71238.09ANI_1\_1226134Citrate synthase (*mcsA*)An15g01920Mito76.6061.8982.5585.78ANI_1\_1474074Citrate synthase (*citB*)An08g10920Cytosol3.053.102.8710,838.65ANI_1\_2950014Citrate synthase (*citC*)An01g09940Cytosol463.10370.88438.0896.44*PrpD family* (*CadA like*)ANI_1\_1536084Immune-responsive proteinAn09g06220Cytosol0.300.230.360.43ANI_1\_2952014Immune-responsive proteinAn01g09950Cytosol552.06456.98383.21165.41ANI_1\_29480142-Methylcitrate dehydrataseAn01g09930Cytosol308.68261.08288.92145.66ANI_1\_3352024MmgE_PrpD superfamily proteinAn02g14730Cytosol5.977.295.8110.08*OahA class family*ANI_1\_92174Oxaloacetate acetylhydrolase (*oahA*)An10g00820Cytosol1803.481122.69323.449.81ANI_1\_2054064Oxaloacetate acetylhydrolaseAn07g08390Cytosol10.417.317.5511.70ANI_1\_1800134Oxaloacetate hydrolase class proteinAn15g07720Cytosol49.6370.4395.0967.85*IA bioconversion*ANI_1\_1432064Itaconyl-CoA transferase A (*ictA*)An07g00760Mito13.07108.35170.34375.89ANI_1\_676164CoA transferase superfamily enzymeAn18g05120Mito11.109.3611.799.99ANI_1\_2118064Itaconyl-CoA hydratase A (*ichA*)An07g09220Mito7.3260.28146.61232.65ANI_1\_316154HTD2 proteinAn17g02190Mito23.6922.2622.3926.75ANI_1\_1156014Citramalate-CoA lyase (*cclA*)An01g08610Mito10.1712.5921.4319.54ANI_1\_864144Trans-aconitate 2-methyltransferase (*tmtA*)An16g06510Mito12.7120.5167.34218.46ANI_1\_830134UMTA methyltransferase family proteinAn15g06160Per/Cytosol15.5211.4552.1123.02

Interestingly, also another previously uncharacterized gene showed similar induction in expression as *ictA* and *ichA* in high producing IA strains. Upon closer inspection this gene product (An16g06510) shares 43% homology with *Escherichia coli* trans-aconitate 2-methyltransferase Tam, which is identified by Zhao et al. as potential gene product that esterifies itaconate into 1-methyl itaconate in the yeast *Saccharomyces cerevisiae* \[[@CR31]\]. Tam reportedly shares the same molecular function as the yeast trans-aconitate 3-methyltransferase TMT1 i.e. methylation of spontaneously formed trans-aconitate in order to relieve cytosolic toxicity by trans-aconitate mediated inhibition of aconitase \[[@CR32], [@CR33]\].

Deletion of *ictA* and *ichA* {#Sec12}
-----------------------------

In our transcriptome analysis we observed that the expression of *ictA* and *ichA* is upregulated in high IA producing strain CitB99. In *A*. *terreus* homologues of both gene products IctA and IchA have been shown to participate in a pathway that intracellularly convert IA into pyruvate and acetyl-CoA \[[@CR29]\]. Based on these observations it was considered that knocking-out *ictA* and *ichA* would improve IA production. Bi-partite fragments were generated and transformed into CitB99. After transformation 89 colonies were visible on transformation plates. 24 colonies of each transformation were cultivated in microtiter plates for colony PCR. 4 colonies of CitB99 ΔICT were shown to be positive for deletion of the *ictA* gene and 6 colonies CitB99 ΔICH were positive for deletion of *ichA* (data not shown). To test for the effect of Δ*ictA* and Δ*ichA* on IA production in-time one CitB99 ΔICT and one CitB99 ΔICH strain were analyzed in flask experiments.

Flask cultivation of CitB99 ΔICT and CitB99 ΔICH {#Sec13}
------------------------------------------------

The IA production of CitB99 ΔICT and CitB99 ΔICH were analyzed in flask experiments in order to test for the effect of Δ*ictA* and Δ*ichA* on IA production. In line with results obtained for CA production in *A*. *niger* \[[@CR17]\] we have observed that under non-shaken conditions more reproducible CA and IA production levels could be obtained (Hossain AH et al. unpublished). Therefore Erlenmeyer flasks were inoculated with 1.0 × 10^6^ conidia/mL and incubated at 33 °C without shaking. From the results depicted in Fig. [1](#Fig1){ref-type="fig"}a it can be seen that IA production starts and proceeds very similar between CitB99 and CitB99 ΔICT up until 144 h of incubation, after which CitB99 ΔICT continues producing IA at a higher rate than CitB99. IA production in CitB99 reaches a plateau at 24.2 g/L after 240 h incubation before IA levels start to decline, due to degradation or bioconversion. Interestingly IA production in CitB99 ΔICT continues and reaches a final titer of 33.52 g/L IA after 336 h of incubation even after glucose is depleted in CitB99 ΔICT cultivation after 288 h (Fig. [1](#Fig1){ref-type="fig"}b). IA production in CitB99 ΔICH however, proceeds at a slower rate compared to CitB99 and CitB99 ΔICT. The final titer that is reached with this strain is much lower than CitB99 ΔICT at 26.39 g/L after 336 h but higher than the final titer of CitB99 due to the lack of degradation most likely. No side-product formation *e.g*. citrate or oxalate has been observed using HPLC analysis. These results show that IA detoxification can be inhibited by deleting *ictA* or *ichA* in *A*. *niger*. CitB99 ΔICT and CitB99 ΔICH were further tested in controlled-batch cultivations at 5-L scale.Fig. 1Non-shaking flask cultivation of CitB99 ΔICT, CitB99 ΔICH and CitB99. Non-baffled 500 mL shake flasks were inoculated with 1.0 × 10^6^ conidia/mL medium and incubated at 33 °C 0 RPM. The experiment was performed in duplicate. **a** Itaconic acid production, **b** glucose consumption during cultivation

Controlled-batch cultivation {#Sec14}
----------------------------

Previously, we have observed a slight decrease in IA titers during the end of controlled-batch fermentations \[[@CR13], [@CR18]\]. In order to further test the IA production of strains CitB99 ΔICT and CitB99 ΔICH we performed controlled-batch cultivations at 5L scale. The fermenters were inoculated with 100 mL 3 days old pre-cultures and DO was set at 20% saturation after inoculation. Glucose consumption, biomass formation and IA production started after 24 h of incubation. Glucose was depleted after 312 h for CitB99 ΔICT and after 324 h for CitB99 ΔICH at which point IA titer reached 28.7 and 24.3 g/L IA respectively (Fig. [2](#Fig2){ref-type="fig"}a). The fermentation was allowed to run for two more days to see if IA would drop in the glucose depleted cultures (Fig. [2](#Fig2){ref-type="fig"}b). The experiment was terminated after 380 h incubation in which no drop in IA levels were measured even after glucose had been depleted. The final titers reached were 29.2 g/L for CitB99 ΔICT and 25.7 g/L for CitB99 ΔICH.Fig. 2Controlled-batch cultivation of CitB99 ΔICT and CitB99 ΔICH. Three day grown pre-cultures were used to inoculate 5L controlled-batch cultivations. **a** IA production of CitB99 ΔICT and CitB99 ΔICH. **b** Glucose consumption and biomass formation of CitB99 ΔICT and CitB99 ΔICH

Deletion of *tmtA* {#Sec15}
------------------

In order to investigate the role of TmtA in itaconate bioconversion, *tmtA* was disrupted in CitB99. After transformation 96 colonies were screened for knock-out using colony PCR and strain CitB99 Δ*tmtA* D6 was found to be a clean knock-out. IA production of CitB99 Δ*tmtA* D6 was further investigated by cultivation in shake flasks. However, HPLC analysis of shake flask cultivations with CitB99 Δ*tmtA* D6 and CitB99 (parental strain) in M12 ++ medium showed that IA production of CitB99 Δ*tmtA* D6 was negatively affected, achieving a max. titre of only 0.9 g/L IA compared to a max titre of 15.6 g/L IA achieved by the parental strain (Fig. [3](#Fig3){ref-type="fig"}a). Interestingly, glucose consumption was comparable between the two strains, suggesting that primary metabolism of glucose might not be affected in the Δ*tmtA* strain despite the low production of IA (Fig. [3](#Fig3){ref-type="fig"}b). Elevated levels of other organic compounds, including trans-aconitate and citrate, were not detected in the supernatant (data not shown). These results indicate that knock-out of *tmtA* does not result in the same desired phenotype in IA production as Δ*ictA* and Δ*ichA* has and as a result we did not proceed with 5L controlled-batch cultivations with this strain.Fig. 3IA production of CitB99 Δ*tmtA* D6 and the parental CitB99 strain. Non-baffled 500 mL shake flasks were inoculated with 1.0 × 10^6^ conidia/mL medium and incubated at 33 °C and 250 RPM. **a** Itaconic acid production, **b** glucose consumption during cultivation

Discussion {#Sec16}
==========

In our attempt at identifying unknown IA bioconversion pathways in *A*. *niger* we have performed a transcriptome analysis of high, medium and low IA producing strains. Interestingly, this analysis led to the identification of at least two novel organic acid bioconversion pathways that were not observed before (Fig. [4](#Fig4){ref-type="fig"}). IA is putatively converted into pyruvate and acetyl-CoA through the combined activity of IctA, IchA and CclA. Also, IA is putatively converted into 1-methyl itaconate through the activity of TmtA in yet another bioconversion pathway.Fig. 4Hypothetical model of IA bioconversion in *A*. *niger*. Itaconate bioconversion presumably takes place in the mitochondrion where itaconate is converted to itaconyl-CoA by action of IctA and further hydrated to citramalyl-CoA by IchA. CclA facilitates the final conversion of citramalyl-CoA into pyruvate and acetyl-CoA. Concomitantly an parallel pathway can convert itaconate into 1-methyl itaconate

Our observation that knock-out strains of *ictA* and *ichA* show increased production of IA and are not able to degrade IA corroborate with the results of Chen et al. \[[@CR29]\], that this pathway indeed converts IA intracellularly. Although CitB99 ΔICT strain is able to achieve higher titers than the CitB99 ΔICH strain, we observed that deletion of *ictA* appears to have the same effect as *ichA* i.e. both knock-out strains are unable to degrade IA. One remarkable feature of the parental strain CitB99 is that the strain performs variably in fermentations where high and low IA production can be seen (data not shown), whereas IA production appears to be more stable in CitB99 ΔICT (data not shown). Our results also suggest that no other enzyme is able to convert itaconate into itaconyl-CoA in the absence of IctA and also that itaconate bioconversion cannot proceed without the activity of IchA. Interestingly, CitB99 ΔICH achieves lower IA end titers than CitB99 ΔICT, possibly due to intracellular accumulation of itaconyl-CoA. However, the fate of IctA-mediated itaconyl-CoA accumulation in the CitB99 ΔICH strain remains unclear. Interestingly, the intracellular accumulation of itaconyl-CoA has been linked to decreased vitamin B12 levels in human brown adipocytes by Shen H et al. These researchers found that itaconyl-CoA can have a toxic influence by competitive inhibition of the mitochondrial vitamin B12-dependent methylmalonyl-CoA mutase (*mut*). This inhibition is mediated by converting vitamin B12 into the chemically inactive cob(II)alamin, thereby decreasing intracellular vitamin B12 levels \[[@CR34]\]. Although fungi are not reported in literature to be able to synthesize nor use vitamin B12 as cofactor in biochemical reactions it cannot be excluded that a similar itaconyl-CoA mediated toxicity might be elicited \[[@CR35]\]. Intracellular itaconyl-CoA accumulation might also exert a similar toxicity response as propionyl-CoA in *Aspergillus nidulans*. Brock M and Buckel W found that intracellular accumulation of propionyl-CoA mainly affects enzymes involved in glucose metabolism, thereby severely retarding growth \[[@CR36]\]. However, as no apparent toxic effects of itaconyl-CoA accumulation were detected on growth and biomass formation in the CitB99 ΔICH strain, further research is required to investigate any potential toxic side-effects of itaconyl-CoA accumulation on fungal physiology.

Interestingly, the identified IA bioconversion pathway appears to share common features with bacterial C5-dicarboxylic acid metabolism, which can use C5 dicarboxylates such as itaconate, mesaconate and citramalate as growth substrates \[[@CR37]\]. Pathogenic bacteria have been shown to use this pathway as a means to evade the hosts cellular defense mechanism during infection \[[@CR30], [@CR38]\]. Similarly *A*. *niger* may use this IA bioconversion pathway as defense mechanism during biological warfare. In nature *A*. *niger* and *A*. *terreus* share many common growth habitats and are constantly in conflict over scarce resources. However, the link between *Aspergillus niger* IA bioconversion and central metabolism is not known and is subject to further investigation.

Remarkably, in the high IA producing strain CitB\#99 *ictA* and *ichA* show similar high levels of induction in expression compared to expression in the AB1.13 strain, however *cclA* does not show the same induction as *ictA* and *ichA*, suggesting that another protein has its function. An alternative possibility might be that IA is converted into an unknown compound in *A*. *niger*. We have detected unknown peaks in the HPLC samples of cultivations with high IA producing strains. The identification of these peaks and unraveling the link to IA detoxification however, is topic of ongoing research.

Interestingly, the second identified putative IA bioconversion pathway involves TmtA that supposedly converts IA into 1-methyl itaconate \[[@CR31]\]. *tmtA* shows similar induction in expression as *ictA* and *ichA* from AB1.13 to CitB\#99, possibly suggesting a role in IA bioconversion. *A*. *niger* TmtA shows sequence similarity of 28% with *S*. *cerevisiae* Tmt1 at a query coverage of 26% and 44% sequence similarity with *E*. *coli* Tam at 91% query coverage. Functional characterization of Tmt1 and Tam has led to the identification of trans-aconitate methyltransferase activity of both enzymes \[[@CR32]\]. Remarkably, Tmt1 was also found to have low-level affinity for IA \[[@CR33]\]. Katz et al. further elucidated that the major endogenous substrate for Tmt1 is an intermediate in the leucine biosynthesis pathway, 3-isopropylmalate, and that Tmt1 functions as a so called 'moonlighting' enzyme i.e. an enzyme that can perform multiple functions in different pathways \[[@CR39]\]. The proposed role that Tmt1 plays in the citric acid cycle is detoxification of spontaneously formed trans-aconitate, an potent inhibitor of aconitase. However the physiologic function of methylating 3-isopropylmalate still requires elucidation \[[@CR33], [@CR39]\]. TmtA could perform a similar moonlighting function in *A*. *niger* where it methylates trans-aconitate and itaconate. Interestingly, deleting *tmtA* results in almost complete shutdown of IA production in *A*. *niger*. This may be caused by an accumulation of trans-aconitate in the mitochondrion and concomitantly the inhibition of aconitase, decreasing the flux to cis-aconitate. Interestingly, no other side-product such as CA was observed in the Δ*tmtA* strain. How TmtA exactly fits in heterologous IA production and overall central metabolism in *A*. *niger* is not entirely clear and is subject of further research. However from the data presented it is apparent that deletion of *tmtA* does not play any role in reducing IA bioconversion.

Remarkably, all of the enzymes involved in IA bioconversion IctA, IchA, CclA and TmtA carry predicted mitochondrial targeting sequences (Table [3](#Tab3){ref-type="table"}). However, for IA bioconversion to take place in the mitochondrion, IA has to be first transported into the cytosol from the extracellular medium and concomitantly transported into the mitochondrion. It is currently unknown which transporters are involved in the transport across the plasma and mitochondrial membrane. However, in our transcriptome data multiple solute transporters have been identified making this a topic for further investigation.

In our research, apart from IA bioconversion pathways, we also looked at other potentially competing biosynthetic pathways that could hamper IA production. One possible way in which IA production might be hampered is when competing organic acid biosynthesis pathways are pulling precursor molecules, e.g. pyruvic acid or oxaloacetate, towards them. In *A*. *niger* one such competing pathway might lead to the formation of l-lactate \[[@CR40]\]. Although a l-lactate dehydrogenase gene is annotated by sequence homology in *Aspergillus niger* (An04g08220) a functional l-lactate dehydrogenase enzyme has not been characterized yet \[[@CR41]\]. Although *A*. *niger* strains are known to be potent oxalic acid producers, we have seen in our transcriptome data that the expression of the key gene for oxalate production i.e. *oahA* is significantly downregulated in CitB\#99, indicating less competition from this pathway for precursor molecules.

In our research (Table [3](#Tab3){ref-type="table"}), we have also found a non-canonical cytosolic citrate synthase similar to the previously identified *citB* \[[@CR18]\]. This *citC* gene (An01g09940) is actually downregulated under *citB*-mediated improvement of IA production. Interestingly, also upon overexpression of *citC* we have observed similar positive effects on IA production (Additional file [7](#MOESM7){ref-type="media"}). Interestingly, similar as *citB* also *citC* appears to be clustered in a secondary metabolite gene cluster carrying two genes encoding CadA-like enzymes (An01g09930 and An01g09950). These results suggest that rewiring of secondary metabolism of *A*. *niger* towards IA production is much more intricate than we previously suspected.

Interestingly, our transcriptome data also indicates upregulation of phosphorus scavenging enzymes like acid phosphatase and phytase. Organic acid production in *A*. *niger* has been linked with phosphate depletion in the past \[[@CR42], [@CR43]\]. Recently, Upton et al. have shown that in phosphate limited citric acid production medium phosphate is quickly taken up by *A*. *niger* and stored as polyphosphate. The researchers further suggest that polyphosphate hydrolysis poses a constraint that limits growth and enables flux of carbon to organic acid production \[[@CR44]\]. Whether a similar response occurs and if polyphosphate putatively fulfills a similar role during heterologous IA production in *A*. *niger* is not clear and warrants further research. Furthermore we have observed strong reduction in expression of genes encoding products that are involved in N transport and utilization, whose functional relation with heterologous IA production is not clear and also topic for further research.

Conclusion {#Sec17}
==========

In our attempt to identify genes involved in putative IA bioconversion in *A*. *niger* we have analyzed a transcriptome dataset from batch fermentations of low, medium and high IA producing *A*. *niger* strains.

Transcriptome analysis has led us to two novel IA conversion pathways in *A*. *niger*. These pathways are not induced in non-IA producing conditions, strongly suggesting that they are specific for IA. One pathway shares homology with a recently identified IA degradation pathway identified in *A*. *terreus* through the combined action of IctA, IchA, and CclA. Upon deleting *ictA* or *ichA* we observed cessation of IA bioconversion and an increase in IA production titers.

Furthermore we identified a second putative IA bioconversion pathway in *A*. *niger* that supposedly converts IA into 1-methyl itaconate through the methylating activity of TmtA. Upon deleting *tmtA* we observed almost complete cessation of IA production, whereas overall growth and glucose consumption did not appear to be affected. Based on these observations we postulate that TmtA is an enzyme that esterifies spontaneously formed trans-aconitate and thereby relieves the cell of potential toxic effects of trans-aconitate accumulation. The results presented in this research contribute in further elucidation of heterologous IA production in *A*. *niger*.
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